Condition: Hepatocellular Carcinoma · Gastric Cancer · Sponsor: Teclison Ltd.
This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.
This description comes directly from the study's public registry record.
Ray Lee, MD. PhD · 8043341076 · ray.lee01@teclison.com
Chiwei Lu, PhD. · chiwei.lu4@teclison.com
Always discuss trial participation with your own doctor first.
| University of California, Irvine | Orange, California, United States | Recruiting |
| University of Oklahoma Health Science Center | Oklahoma City, Oklahoma, United States | Recruiting |
| Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03259867